Symphony is a compendium of four assays to support BC treatment decisions: (a) MammaPrint which determines the risk of recurrence; (b) BluePrint which determines molecular subtypes; (c) TargetPrint determines ER, PR and HER2 status; and (d) TheraPrint which identifies alternative types of therapy for metastatic disease. This evidence concerns the gene ESR1 and breast cancer.